Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. The funds are aimed at accelerating the pivotal Phase 2b/3 trial for its promising Alzheimer’s treatment, Xanamem. This decisive move aims to fast-track patient enrolment and bring the potential breakthrough […]